CLYM

SEC filing CLYM Reports $110M Private Placement, $19B Revenue, +94% YoY, Subcutaneous Budoprutug Shows Robust B-Cell Depletion, Phase 1b/2a ITP Data Expected June 2026, PrisMN Phase 2 Fast Track Designation Granted, Anticipate Q4 2026 Anti-PLA2R and SLE B-Cell Data, Initiate Multiple-Dose A

26d ago

SEC filing CLYM Reports Subcutaneous Budoprutug Data, Fast Track pMN, ITP, SLE Trials, June & Q4 Readouts, Webcast Today

28d ago

SEC filing CLYM Reports $0 Revenue, $0 EPS, Updates Budoprutug Phase 1b/2a ITP Data H2 2026, CLYM116 Phase 1 Enrollment Ongoing, Cash Runway to 2028

89d ago

Insider trade Sale by Stephen Basil Thomas

94d ago

Insider trade Sale by Stephen Basil Thomas

104d ago

News Trump Says Federal Intel Stake Has Made 'Tens Of Billions': Stock Climbs

144d ago

News H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks

153d ago

News Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target

153d ago

News Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

156d ago

Scanner Unusual volume (z=25.0)

168d ago

Scanner Unusual volume (z=25.9)

169d ago

Scanner Unusual volume (z=25.9)

170d ago

Scanner Unusual volume (z=3.6)

171d ago